ReviewInfection and drug resistance2018
Pathogenesis and management of adenoviral keratoconjunctivitis.
Review in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial.International ophthalmology · 2020Trial
- Asia's eye health challenge: unravelling the spread and solutions for conjunctivitis.International ophthalmology · 2026Review
- Evaluation of the effect of subepithelial infiltrates following adenoviral keratoconjunctivitis on corneal biomechanics: Corvis ST analysis.BMC ophthalmology · 2026Article
- Long-term effects of adenoviral keratoconjunctivitis on conjunctival goblet cell density and tear film parameters: a prospective case-control study.BMC ophthalmology · 2026Article
- The Emergence Potential ofArchives of Razi Institute · 2024Review
- Common and Potential Emerging Foodborne Viruses: A Comprehensive Review.Life (Basel, Switzerland) · 2024Review
- Global Prevalence of Preexisting Antibodies against Human Adenoviruses, Surveyed from 1962 to 2021.Intervirology · 2024Review
- Systems approach to design multi-epitopic peptide vaccine candidate against fowl adenovirus structural proteins forFrontiers in cellular and infection microbiology · 2024Article
- In Vitro efficacy of cyclosporine a and various antiseptics and antiviral drugs on adenovirus genotype 8, a common cause of epidemic keratoconjunctivitis.International ophthalmology · 2023Article
- Case for conservative management of adenoviral pseudomembranous conjunctivitis.BMJ case reports · 2023Article
- Molecular Epidemiology of Adenoviral Keratoconjunctivitis in Korea.Annals of laboratory medicine · 2022Article
- Antiviral Drugs in Adenovirus-Induced Keratoconjunctivitis.Microorganisms · 2022Review
- Evolution and diversity of human adenoviruses isolated from patients with keratoconjunctivitis.Iranian journal of microbiology · 2022Article
- Human adenovirus infections in pediatric population - An update on clinico-pathologic correlation.Biomedical journal · 2022Review
- Epidemic keratoconjunctivitis: efficacy of outbreak management.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Article
- Predictive Accuracy and Densitometric Analysis of Point-of-Care Immunoassay for Adenoviral Conjunctivitis.Translational vision science & technology · 2021Article
- The Transmission of SARS-CoV-2 Infection on the Ocular Surface and Prevention Strategies.Cells · 2021Review
- SARS-COV-2 and Ocular Surface: From Physiology to Pathology, a Route to Understand Transmission and Disease.Frontiers in physiology · 2021Review
- Filociclovir Is a PotentAntimicrobial agents and chemotherapy · 2020Article
- Management of Adenoviral Keratoconjunctivitis: Challenges and Solutions.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human adenovirus (HAdV) is a ubiquitous virus that infects the mucosa of the eye. It is the most common cause of infectious conjunctivitis worldwide, affecting people of all ages and demographics. Pharyngoconjunctival fever outbreak is due to HAdV types 3, 4, and 7, whereas outbreaks of epidemic keratoconjunctivitis are usually caused by HAdV types 8, 19, 37, and 54. Primary cellular receptors, such as CAR, CD46, and sialic acid interact with fiber-knob protein to mediate adenoviral attachment to the host cell, whereas adenoviral penton base-integrin interaction mediates internalization of adenovirus. Type 1 immunoresponse to adenoviral ocular infection involves both innate immunity mediated by natural killer cells and type 1 interferon, as well as adaptive immunity mediated mainly by CD8 T cells. The resulting ocular manifestations are widely variable, with pharyngoconjunctival fever being the most common, manifesting clinically with fever, pharyngitis, and follicular conjunctivitis. Epidemic keratoconjunctivitis, however, is the severest form, with additional involvement of the cornea leading to development of subepithelial infiltrates. Because there is currently no US Food and Drug Administration-approved treatment for adenoviral ocular infection, current management is palliative. The presence of sight-threatening complications following ocular adenoviral infection warrants the necessity for developing antiadenoviral therapy with enhanced therapeutic index. Future trends that focus on adenoviral pathogenesis, including adenoviral protein, which utilize host receptors to promote infection, could be potential therapeutic targets, yielding shorter active disease duration and reduced disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.